Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 0.72 USD -2.7% Market Closed
Market Cap: 20.7m USD
Have any thoughts about
Cyclo Therapeutics Inc?
Write Note

Cyclo Therapeutics Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cyclo Therapeutics Inc
Operating Expenses Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Cyclo Therapeutics Inc
NASDAQ:CYTH
Operating Expenses
-$22.2m
CAGR 3-Years
-21%
CAGR 5-Years
-29%
CAGR 10-Years
-35%
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$21.9B
CAGR 3-Years
-4%
CAGR 5-Years
-12%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.2B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.4B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$4.9B
CAGR 3-Years
-10%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$7.8B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is Cyclo Therapeutics Inc's Operating Expenses?
Operating Expenses
-22.2m USD

Based on the financial report for Jun 30, 2024, Cyclo Therapeutics Inc's Operating Expenses amounts to -22.2m USD.

What is Cyclo Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-35%

Over the last year, the Operating Expenses growth was -13%. The average annual Operating Expenses growth rates for Cyclo Therapeutics Inc have been -21% over the past three years , -29% over the past five years , and -35% over the past ten years .

Back to Top